Baxter International Inc. (BAX) Return on Assets (ROA): -5.53%
Is Baxter International Inc.’s return on assets (ROA) high or low?
Baxter International Inc.'s return on assets (ROA) of -5.53% is 1272% below its 5-year average of 0.47%, near the low end of its 5-year range (-8.60%–9.39%).
As of Thursday, June 11, 2026. 51.71% below its 12-month average of -3.64%.
BAX Return on Assets (ROA) Chart
BAX Average Return on Assets (ROA) Chart
BAX Current vs Average Return on Assets (ROA) Chart
BAX Return on Assets (ROA) Metrics
RETURN ON ASSETS (ROA)
-5.53%
RETURN ON ASSETS (ROA) AVG TTM
-3.64%
RETURN ON ASSETS (ROA) AVG 3Y
-1.62%
RETURN ON ASSETS (ROA) AVG 5Y
0.47%
RETURN ON ASSETS (ROA) AVG 10Y
5.29%
RETURN ON ASSETS (ROA) AVG 15Y
6.69%
RETURN ON ASSETS (ROA) AVG 20Y
7.66%
CURRENT VS TTM AVG
-51.71%
CURRENT VS 3Y AVG
-240.31%
CURRENT VS 5Y AVG
-1272.44%
CURRENT VS 10Y AVG
-204.45%
CURRENT VS 15Y AVG
-182.72%
CURRENT VS 20Y AVG
-172.17%
BAX Competitors' Return on Assets (ROA)
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Baxter International Inc. (BAX) | $10.58B | -5.53% | -3.64% | -1.62% | 0.47% |
| Charles River Laboratories International, Inc. (CRL) | $9.06B | -2.39% | -0.94% | 2.58% | 3.75% |
| Tempus AI, Inc. (TEM) | $8.65B | -14.19% | -43.49% | -42.71% | -41.26% |
| Align Technology, Inc. (ALGN) | $12.64B | 6.81% | 6.68% | 6.69% | 12.75% |
| Bio-Rad Laboratories, Inc. (BIO) | $7.91B | 1.72% | -6.26% | -11.14% | 1.46% |
| Solventum Corporation (SOLV) | $13.72B | 10.16% | 7.10% | 8.43% | 7.35% |
| Hims & Hers Health, Inc. (HIMS) | $6.44B | -0.58% | 11.88% | 0.12% | -6.73% |
| Hologic, Inc. (HOLX) | $16.97B | 5.92% | 7.45% | 8.56% | 11.79% |
| Moderna, Inc. (MRNA) | $19.70B | -27.80% | -24.02% | -10.32% | -0.33% |
| 23andMe Holding Co. (ME) | $15.31M | -163.04% | -172.19% | -99.08% | -83.15% |
Asset Efficiency
ROA
-5.5%
ROE
-18.2%
Baxter International Inc. Return on Assets (ROA) Formula & Definition
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Baxter International Inc. Return on Assets (ROA) FAQ
- What is the return on assets (ROA) for Baxter International Inc. (BAX)?
- The return on assets (ROA) for BAX stock is -5.53%.
- Is Baxter International Inc.'s return on assets (ROA) high or low?
- Baxter International Inc.'s return on assets (ROA) of -5.53% is 1272% below its 5-year average of 0.47%, near the low end of its 5-year range (-8.60%–9.39%).
- What is the TTM average return on assets (ROA) for Baxter International Inc. (BAX)?
- The TTM average return on assets (ROA) for BAX stock is -3.64%.
- What is the 3Y average return on assets (ROA) for Baxter International Inc. (BAX)?
- The 3Y average return on assets (ROA) for BAX stock is -1.62%.
- What is the 5Y average return on assets (ROA) for Baxter International Inc. (BAX)?
- The 5Y average return on assets (ROA) for BAX stock is 0.47%.
- What is the 10Y average return on assets (ROA) for Baxter International Inc. (BAX)?
- The 10Y average return on assets (ROA) for BAX stock is 5.29%.
- What is the 15Y average return on assets (ROA) for Baxter International Inc. (BAX)?
- The 15Y average return on assets (ROA) for BAX stock is 6.69%.
- What is the 20Y average return on assets (ROA) for Baxter International Inc. (BAX)?
- The 20Y average return on assets (ROA) for BAX stock is 7.66%.
Baxter International Inc. Return on Assets (ROA) History
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -4.77% |
| 2024-12-31 | -2.52% |
| 2023-12-31 | 9.39% |
| 2022-12-31 | -8.60% |
| 2021-12-31 | 3.83% |
| 2020-12-31 | 5.50% |
| 2019-12-31 | 5.50% |
| 2018-12-31 | 9.83% |
| 2017-12-31 | 3.52% |
| 2016-12-31 | 31.94% |
| 2015-12-31 | 4.62% |
| 2014-12-31 | 9.55% |
| 2013-12-31 | 7.98% |
| 2012-12-31 | 11.41% |
| 2011-12-31 | 11.66% |
| 2010-12-31 | 8.12% |
| 2009-12-31 | 12.71% |
| 2008-12-31 | 13.07% |
| 2007-12-31 | 11.16% |
| 2006-12-31 | 9.51% |
| 2005-12-31 | 7.51% |
| 2004-12-31 | 2.74% |
| 2003-12-31 | 6.32% |
| 2002-12-31 | 6.18% |
| 2001-12-31 | 5.92% |
| 2000-12-31 | 8.47% |
| 1999-12-31 | 8.26% |
| 1998-12-31 | 3.19% |
| 1997-12-31 | 3.45% |
| 1996-12-31 | 8.81% |
Related Metrics
About Baxter International Inc.
Baxter International Inc., operating globally via its subsidiaries, is a leading developer and provider of a wide spectrum of healthcare products. The company's comprehensive portfolio includes various dialysis treatments, such as peritoneal and hemodialysis, along with related therapies and services. It also specializes in intravenous (IV) therapies, infusion pumps, administration sets, and devices for drug reconstitution. Further expanding its pharmaceutical offerings, Baxter delivers pre-mixed and oncology drug platforms, inhaled anesthetic agents, critical care products, and pharmacy compounding services. Nutritional support is provided through its parenteral nutrition therapies and associated products. For surgical procedures, the company develops biological products and medical devices vital for achieving hemostasis, tissue sealing, and preventing adhesions. Additionally, Baxter supplies continuous renal replacement therapies (CRRT) and other organ support solutions, primarily tailored for intensive care units. Beyond direct medical supplies, Baxter provides sophisticated connected care solutions, integrating devices, software, communication systems, and other advanced technologies. This includes a range of patient monitoring and diagnostic technologies designed to aid in the diagnosis, treatment, and management of numerous illnesses and conditions, spanning respiratory therapy, cardiology, vision screening, and physical assessment. The surgical suite benefits from its specialized video technologies, operating tables, lights, pendants, precision positioning tools, and various ancillary accessories. The company also offers contracted services to a multitude of pharmaceutical and biopharmaceutical companies. Baxter's products are utilized across diverse healthcare environments, including hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices, and for home-based patients under medical supervision. Operating in approximately 100 countries, Baxter distributes its extensive product line through a direct sales force, independent distributors, drug wholesalers, and specialty pharmacies or other alternative site providers. The company also holds a collaborative agreement with Celerity Pharmaceutical, LLC, focused on developing generic injectable pre-mixed medications for acute care and oncolytic molecules. Established in 1931, Baxter International Inc. is headquartered in Deerfield, Illinois.
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- CEO
- Andrew Hider